pdf (Español (España))
FLIP
How to Cite
Henry Osorio, J. ., & Bolaños, N. . (2019). Management of chronic pain with Cannabis extract in a group of patients in the city of Manizales. Biosalud, 18(1), 22–25. https://doi.org/10.17151/biosa.2019.18.1.2
More Citation Formats
Authors
José Henry Osorio
Perfil Google Scholar
Nataly Bolaños
Abstract
Chronic pain is a public health problem. During the last decade, various drugs have been introduced to manage different types of pain, cannabinoids among them. Materials and methods: the evaluation of chronic pain treatment in a group of patients from Manizales (Colombia), using five different preparations of Δ9-Tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) is presented in this study. Results: On average, the values of the numeric pain scale (1-10) before the exposure to the five concentrations of cannabis extracts were 7,33; 7,75; 7,33; 7,94 and 7,33 respectively before the treatment, and 3,50; 4,40; 4,00; 4,72 and 3,17 respectively after the treatment. Conclusion: It can be concluded that a decrease in the pain level was observed after using cannabinoids, presenting similar results between the different solutions used.
Keywords:
References
1. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71(1):37-48.
2. Chen C-Y, O’Brien MS, Anthony JC. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend 2005; 79
(1):1122.
3. Vale A. Cannabis. Medicine 2007; 35(11):603.
4. Grotenhermen F. Los cannabinoides y el sistema endocannabinoide. Cannabinoids 2006; 1(1):10-14.
5. Ministerio de Sanidad y Consumo de España. Guía de Práctica Clínica sobre Cuidados Paliativos. Madrid: Plan Nacional para el SNS del MSC. Primera ed. Bilbao: Agencia de Evaluación de Tecnologías Sanitarias del País Vasco; 2008. Pp 223.
6. Von Korff M Opioids for chronic musculoskeletal pain: putting patient safety first. Pain 2013; 154(12):2583–2585.
7. Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebocontrolled studies of at least 4 weeks duration]. Schmerz 2015; 29(1):47-59.
8. Häuser W, Walitt B, Fitzcharles MA, Sommer C Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther 2014; 16:201
9. Petzke F, Welsch P, Klose P, Schaefert R, Sommer C, Häuser W. Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebocontrolled studies of at least 4 weeks duration]. Schmerz 2015; 29(1):60-72.
10. Alcántara-Montero A, González-Curado A. Cannabis en el tratamiento del dolor: consideraciones clínicas y de investigación. Rev Soc Esp Dolor 2017; 24(1): 28-43.
11. Bridgeman MB, Abazia DT. Medicinal cannabis: History, pharmacology, and implications for the acute care setting. PT. 2017; 42(3):180-8.
12. Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005; 10: 44a-6ª.
13. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation.Nat Rev Drug Discov 2004; 3(9):771-784
14. Guindon J, Hohmann AG The endocannabinoid system and pain. CNS Neurol Dis Drug Targets 2009; 8:403-42.
15. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012; 204:207-229.
16. Lee MC, Ploner M, Wiech K, Bingel U. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 2013; 154:124-134.
17. Covarrubias-Gómez A. El papel de los canabinoides en el manejo del dolor. Rev Mex Anestesiol 2008; 31 (3):191-200.
18. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182: E694-701.
19. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized
controlled trial. Wien Klin Wochenschr 2006; 118:327-335.
20. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:50-52.
21. Ware MA, Gamsa A, Persson J, Fitzcharles MA. Cannabis for chronic pain: case series and implications for clinicians. Pain Res Manag. 2002; 7(2):95-9.
2. Chen C-Y, O’Brien MS, Anthony JC. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend 2005; 79
(1):1122.
3. Vale A. Cannabis. Medicine 2007; 35(11):603.
4. Grotenhermen F. Los cannabinoides y el sistema endocannabinoide. Cannabinoids 2006; 1(1):10-14.
5. Ministerio de Sanidad y Consumo de España. Guía de Práctica Clínica sobre Cuidados Paliativos. Madrid: Plan Nacional para el SNS del MSC. Primera ed. Bilbao: Agencia de Evaluación de Tecnologías Sanitarias del País Vasco; 2008. Pp 223.
6. Von Korff M Opioids for chronic musculoskeletal pain: putting patient safety first. Pain 2013; 154(12):2583–2585.
7. Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebocontrolled studies of at least 4 weeks duration]. Schmerz 2015; 29(1):47-59.
8. Häuser W, Walitt B, Fitzcharles MA, Sommer C Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther 2014; 16:201
9. Petzke F, Welsch P, Klose P, Schaefert R, Sommer C, Häuser W. Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebocontrolled studies of at least 4 weeks duration]. Schmerz 2015; 29(1):60-72.
10. Alcántara-Montero A, González-Curado A. Cannabis en el tratamiento del dolor: consideraciones clínicas y de investigación. Rev Soc Esp Dolor 2017; 24(1): 28-43.
11. Bridgeman MB, Abazia DT. Medicinal cannabis: History, pharmacology, and implications for the acute care setting. PT. 2017; 42(3):180-8.
12. Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005; 10: 44a-6ª.
13. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation.Nat Rev Drug Discov 2004; 3(9):771-784
14. Guindon J, Hohmann AG The endocannabinoid system and pain. CNS Neurol Dis Drug Targets 2009; 8:403-42.
15. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012; 204:207-229.
16. Lee MC, Ploner M, Wiech K, Bingel U. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 2013; 154:124-134.
17. Covarrubias-Gómez A. El papel de los canabinoides en el manejo del dolor. Rev Mex Anestesiol 2008; 31 (3):191-200.
18. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182: E694-701.
19. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized
controlled trial. Wien Klin Wochenschr 2006; 118:327-335.
20. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:50-52.
21. Ware MA, Gamsa A, Persson J, Fitzcharles MA. Cannabis for chronic pain: case series and implications for clinicians. Pain Res Manag. 2002; 7(2):95-9.
Downloads
Download data is not yet available.
